Tolerance and Excretion of Iohexol after Intravenous Injection in Healthy Volunteers

In extensive animal series the acute toxicity of iohexol injected intravenously was found to be somewhat lower than that of metrizamide (Arnipaque), at present the only non-ionic contrast medium commercially available (SALVESEN 1980). The pharmacodynamic and pharmacokinetic properties of iohexol were found favourable (Acta radiol. (1980) Suppl. No, 362). Based on this documentation iohexol has been released for human testing. The aim of the first human test series, now briefly presented, was to evaluate the safety and tolerability of the contrast medium in healthy volunteers and to elucidate its distribution, possible metabolism and renal excretion (Phase I investigation).